Corporate Profile
HCW Biologics Inc. (Nasdaq: HCWB) is a commercial-and-clinical stage biopharmaceutical company developing first-in-class immunotherapies to revolutionize the treatments for autoimmune diseases, cancer and senescence-associated dysplasia.
By leveraging our extensive immunology expertise, we have developed fusion immunotherapeutics representing a new class of drugs that we believe have the potential to fundamentally change the treatments for autoimmune diseases, cancer, senescence-associated dysplasia, and many other diseases promoted by chronic inflammation — and in doing so, improve patients’ quality of life and possibly extend longevity. The Company utilized its proprietary drug discovery and development platforms to create novel fusion immunotherapeutics, including multi-specific cytokines, targeted second-generation immune checkpoint inhibitors, and immune-cell engagers. Our specialty is to develop treatments administered by subcutaneous injection. Among our lead product candidates, we currently have two proprietary fusion immunotherapeutics that have reached the commercial stage for supporting cell-based therapies for cancer and infectious diseases, and one fusion immunotherapeutic being evaluated in a clinical trial for an autoimmune disease.
HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index
Minimum 15 minutes delayed. Source: LSEG
| Filing date | Description | Form |
|---|---|---|
| Report of unscheduled material events or corporate event | 8-K | |
| Official notification to shareholders of matters to be brought to a vote ("Proxy") | DEF 14A | |
| A preliminary proxy statement providing notification matters to be brought to a vote | PRE 14A | |
| Report of unscheduled material events or corporate event | 8-K | |
| Form of prospectus disclosing information facts events covered in both forms 424B1 424B3 | 424B4 | |
| Report of unscheduled material events or corporate event | 8-K | |
| Amended Registration statement for face-amount certificate companies | S-1/A |